The Peptide Observer

Peptide research, explained for people who are not scientists.

Quick answer

What is Leuprolide?

Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works

Leuprolide is a peptide, grouped on this site under Endocrine and immune signalling peptides, and the 12 research records kept here are 10 from trials in people and 2 that do not state what kind of study it is.

The literature search returned 2,436 records. This site keeps 12 of them, which is 0.49 per cent of what came back.

What it is

This site puts it in the Endocrine and immune signalling peptides group.

A gonadotropin-releasing hormone superagonist; the retrieved records report androgen and oestrogen suppression after sustained-release administration.[1, 2]

Stated in the titles of the cited 1997 Advanced Drug Delivery Reviews and 2014 Journal of Clinical Oncology papers.

What kind of records

Several of the records kept here are trials in people.

That sentence is produced by counting, not by reading. What was counted: 10 of 12 indexed records are interventional human trials by their own assigned publication type.

What this does not settle

Where this comes from

The records cited above, in full.

  1. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Advanced drug delivery reviews (1997). pmid:10837564
  2. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). pmid:25311217